Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07194590 · ClinicalTrials.gov registry record · Phase 2
Equol and Vascular Function in Women With Chronic Kidney Disease
A Phase 2 study, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT07194590 is a Phase 2 study that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 74 participants.
The verdict
NCT07194590, a Phase 2 study, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH. Equol contributes to improvement in vascular function, mediated in part by its anti-oxidative and anti-inflammatory properties. However, there is no information on the effect of equol on vascular function in women with CKD. The proposed project aims to determine the effect of 12 weeks of oral equol supplementation on vascular function in postmenopausal women with CKD.
Interventions
- DRUG Placebo
- DRUG Equol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2026-02-19 |
| Est. Completion | 2030-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07194590
The ClinicalTrials.gov registry entry for NCT07194590 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07194590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07194590 about?
NCT07194590 is a clinical study titled "Equol and Vascular Function in Women With Chronic Kidney Disease". The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literatu...
What is the current status of trial NCT07194590?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2026-02-19. Estimated completion is 2030-11-30.
What interventions are being tested in trial NCT07194590?
The interventions under investigation include: Placebo (DRUG), Equol (DRUG).
Who is sponsoring clinical trial NCT07194590?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.